MCE 國(guó)際站：Pembrolizumab (anti-PD-1)
品牌：MedChemExpress (MCE)
存儲(chǔ)條件：Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性： Pembrolizumab（抗 PD-1）是一種人源化 IgG4 抗體，可抑制程序性細(xì)胞死亡 1 (PD-1) 受體，用于癌癥免疫治療[1]。
銷售產(chǎn)品：Nitrosoglutathione | Daidzein | Luminespib | Pyocyanin | AZD-5991 | Carvedilol | Pinocembrin | MS4322 | Aprepitant | Patritumab deruxtecan
研究領(lǐng)域：Immunology/Inflammation
作用靶點(diǎn)：PD-1/PD-L1
熱門產(chǎn)品線：重組蛋白 | 化合物庫(kù) | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物 | 寡核苷酸
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
參考文獻(xiàn)：
[1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)
會(huì)員.png)
4
立即詢價(jià)
您提交后，專屬客服將第一時(shí)間為您服務(wù)